STRATA Skin Sciences Plunges 25.09% on $2.42M Stock Offering

On September 3, 2025, STRATA Skin Sciences experienced a significant drop of 25.09% in pre-market trading, marking a notable shift in investor sentiment towards the company.

STRATA Skin Sciences recently announced the pricing of a $2.42 million registered direct offering of common stock, selling 1.10 million shares at $2.204 per share. This move is part of the company's strategy to secure additional funding for its operations and growth initiatives.

The company's intellectual property portfolio continues to be a strong point, with key patents that provide exclusivity for combination therapies involving its XTRAC excimer laser. These patents cover the use of the laser with JAK inhibitors, systemic drugs, and biologic drugs, positioning STRATA at the forefront of integrative dermatologic treatment. The company is actively working with CMS to implement expanded CPT codes, which could significantly increase the addressable patient population and improve treatment economics.

STRATA Skin Sciences has also seen a surge in stock price, reflecting investor enthusiasm following promising scientific advancements and market strategy. The company's focus on developing innovative products for dermatologic treatments, such as the XTRAC excimer laser and TheraClear X Acne Therapy System, continues to drive its growth and market presence.